SARS-CoV-2 Pathogenesis, Vaccines and Therapeutics
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "COVID-19 Vaccines and Vaccination".
Deadline for manuscript submissions: 31 May 2026 | Viewed by 563
Special Issue Editor
Interests: development of antiviral small molecules and antibodies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Coronaviruses (CoVs) are RNA viruses that have been a major public health concern since the Severe Acute Respiratory Syndrome-CoV (SARS-CoV) outbreak in 2002. Currently, the world is concerned about SARS-CoV-2, the causative agent of COVID-19, which was initially identified in the city of Wuhan, China, in December 2019. Tens of thousands of cases and several thousand deaths have been reported in many countries. SARS-CoV-2 is highly contagious based on the number of infected cases to date. There is a need for the development of vaccines and effective therapeutics that can control the current outbreak.
We are interested in manuscripts that focus on the replication, viral life cycle, and pathogenesis of SARS-CoV-2. We are also interested in areas of identification of novel drug targets and the development of vaccines and therapeutics for COVID-19. We aim to publish a variety of manuscripts that represent different research studies that investigate unique aspects of viral pathogenesis and life cycles and identify/test different vaccines and antivirals for efficacy against SARS-CoV-2.
I look forward to receiving your contributions.
Dr. Hatem A. Elshabrawy
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- vaccine
- SARS-CoV-2
- COVID-19
- antibodies
- antivirals
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
